Halozyme Therapeutics (NASDAQ:HALO) Releases FY 2026 Earnings Guidance

Key Points

• Halozyme raised its FY 2026 outlook to EPS of $8.65–$9.00 and revenue of $1.8–$1.9 billion, above consensus EPS of $8.02 and roughly in line with the $1.8 billion revenue estimate.
• The company reported quarterly EPS of $2.28, beating estimates of $1.79, while revenue of $481 million exceeded the $402.28 million consensus. Shares rose 2.6% to $85.76.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $81.60; institutional investors own 97.79% of the stock, while insiders sold $5.1 million in shares over the past 90 days.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 8.650-9.000 for the period, compared to the consensus estimate of 8.020. The company issued revenue guidance of $1.8 billion-$1.9 billion, compared to the consensus revenue estimate of $1.8 billion.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. UBS Group reiterated a "buy" rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. HC Wainwright reaffirmed a "buy" rating and set a $95.00 target price on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Weiss Ratings raised shares of Halozyme Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a research note on Friday, July 31st. Wall Street Zen upgraded Halozyme Therapeutics from a "hold" rating to a "buy" rating in a report on Saturday, May 16th. Finally, Morgan Stanley dropped their price objective on Halozyme Therapeutics from $96.00 to $93.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 12th. Eight investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $81.60.

Halozyme Therapeutics Stock Up 2.6%

NASDAQ:HALO traded up $2.17 during mid-day trading on Thursday, reaching $85.76. The company's stock had a trading volume of 2,679,037 shares, compared to its average volume of 1,795,718. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81. Halozyme Therapeutics has a 1 year low of $61.22 and a 1 year high of $86.00. The stock has a fifty day moving average of $75.39 and a 200-day moving average of $71.15. The firm has a market capitalization of $10.17 billion, a PE ratio of 30.85, a price-to-earnings-growth ratio of 0.34 and a beta of 0.85.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating analysts' consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The business had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Equities research analysts forecast that Halozyme Therapeutics will post 7.54 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Mahesh Krishnan sold 7,304 shares of Halozyme Therapeutics stock in a transaction on Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the transaction, the director directly owned 14,462 shares in the company, valued at approximately $1,084,650. This trade represents a 33.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the business's stock in a transaction on Monday, June 1st. The stock was sold at an average price of $67.58, for a total value of $1,351,600.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares of the company's stock, valued at approximately $51,886,572.40. The trade was a 2.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 72,477 shares of company stock valued at $5,102,643 over the last 90 days. Corporate insiders own 2.50% of the company's stock.

Hedge Funds Weigh In On Halozyme Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Arrowstreet Capital Limited Partnership lifted its position in shares of Halozyme Therapeutics by 29.5% during the third quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company's stock valued at $241,337,000 after buying an additional 749,484 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of Halozyme Therapeutics by 1.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,104,157 shares of the biopharmaceutical company's stock worth $141,613,000 after buying an additional 25,731 shares during the last quarter. Federated Hermes Inc. raised its stake in shares of Halozyme Therapeutics by 8.5% during the 4th quarter. Federated Hermes Inc. now owns 1,574,621 shares of the biopharmaceutical company's stock worth $105,972,000 after acquiring an additional 123,917 shares in the last quarter. Fuller & Thaler Asset Management Inc. lifted its position in Halozyme Therapeutics by 0.6% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 1,379,575 shares of the biopharmaceutical company's stock valued at $92,845,000 after acquiring an additional 8,391 shares during the last quarter. Finally, Caisse de depot et placement du Quebec lifted its position in Halozyme Therapeutics by 57.6% during the fourth quarter. Caisse de depot et placement du Quebec now owns 1,224,009 shares of the biopharmaceutical company's stock valued at $82,376,000 after acquiring an additional 447,374 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company's stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source